IL2 and asthma: Other studies have observed a reduction in hyperresponsiveness, eosinophilia and IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-13 and IL-7 in asthma models that received PAR-2 inhibitors and PAR-2 signalling blockers50.